

ASX Announcement

13 February 2026

1H FY26 Results Webinar

BCAL Diagnostics Limited (ASX: BDX) ("BCAL") advises that it will host an investor webinar on Wednesday, 18 February 2026 at 11:00am AEDT.

The webinar will include a presentation from the Company's Executive Chair, Jayne Shaw and Chief Executive Officer, Shane Ryan, followed by a Q&A session.

Investors are invited to register for the webinar via the following [link](#)

A copy of the presentation will be released to the ASX prior to the webinar.

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

Corporate

Shane Ryan

sryan@bcaldiagnostics.com

+61 (0) 437 192 869

Media

Rama Razy

rama.razy@atomicgroup.com.au

+61 (0) 498 440 142

About BCAL

BCAL is an Australian biotechnology company engaged in early multi-cancer detection. BCAL maintains an exclusive licence agreement with ClearNote Health Inc. ("ClearNote Health"), a US-based precision diagnostics company, for the distribution of ClearNote Health's pancreatic and ovarian cancer blood tests in Australia.

BCAL is also focussed on advancing early and accurate breast cancer detection via BREASTEST plus™ a non-invasive, lipid-based 'rule-out' test designed to be used in women with dense breasts and alongside mammography to improve screening and diagnostic outcomes for women.

Founded in 2010, BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.